NCT02062515View on ClinicalTrials.gov

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

June 30, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

icotinib

Icotinib is administered orally 125 mg three times per day continuously for four weeks

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY